InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that it will release its fiscal year 2021 financial report at the end of the week. INM’s full financial statements and related MD&A for the period ending June 30, 2021, will be released on Friday, Sept. 24, 2021. In connection with the release of its financial report, the company will also be hosting a conference call/webcast to discuss the report. The call will begin at 11 a.m. ET. Interested individuals from the United States and Canada can call toll free at 855-605-1745; those who are interested and need to dial in internationally can call 914-987-7959. Callers will need to use conference ID #9373618. A recording of the webcast will be available for 90 days following the event. In addition, InMed announced that it has signed a definitive agreement to acquire BayMedica, a private company based in the United States that specializes in the manufacture and commercialization of rare cannabinoids. The agreement outlines the acquisition terms, which involve an all-stock transaction. According to the announcement, InMed will issue 1.78 million shares to BayMedica’s equity and convertible debt holders, an estimated $4 million value. The strategic move, which will likely close in the coming weeks, will provide InMed with established expertise in yeast and bacteria biosynthesis as well as chemical synthesis of cannabinoids. The company also noted that the move represents cumulative revenues for InMed of more than $2.5 million since December 2019; those revenues are from the sale of cannabichromene (“CBC”).
To view the full webinar, visit https://cnw.fm/QahU7
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.